Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Qualigen Therapeutics stock

Own Qualigen Therapeutics stock in just a few minutes.

Qualigen Therapeutics, Inc is a biotechnology business based in the US. Qualigen Therapeutics shares (QLGN) are listed on the NASDAQ and all prices are listed in US Dollars. Qualigen Therapeutics employs 34 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Qualigen Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – QLGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Qualigen Therapeutics share price

Use our graph to track the performance of QLGN stocks over time.

Qualigen Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$1.71 - $19.75
50-day moving average $2.66
200-day moving average $3.48
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.63

Buy Qualigen Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Qualigen Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Qualigen Therapeutics financials

Revenue TTM $3.8 million
Gross profit TTM $-2,675,581
Return on assets TTM -42.52%
Return on equity TTM -237%
Profit margin 0%
Book value N/A
Market capitalisation $56.1 million

TTM: trailing 12 months

Shorting Qualigen Therapeutics shares

There are currently 1.8 million Qualigen Therapeutics shares held short by investors – that's known as Qualigen Therapeutics's "short interest". This figure is 11.6% down from 2.0 million last month.

There are a few different ways that this level of interest in shorting Qualigen Therapeutics shares can be evaluated.

Qualigen Therapeutics's "short interest ratio" (SIR)

Qualigen Therapeutics's "short interest ratio" (SIR) is the quantity of Qualigen Therapeutics shares currently shorted divided by the average quantity of Qualigen Therapeutics shares traded daily (recently around 915215.46391753). Qualigen Therapeutics's SIR currently stands at 1.94. In other words for every 100,000 Qualigen Therapeutics shares traded daily on the market, roughly 1940 shares are currently held short.

However Qualigen Therapeutics's short interest can also be evaluated against the total number of Qualigen Therapeutics shares, or, against the total number of tradable Qualigen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Qualigen Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Qualigen Therapeutics shares in existence, roughly 60 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Qualigen Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Qualigen Therapeutics.

Find out more about how you can short Qualigen Therapeutics stock.

Qualigen Therapeutics share dividends

We're not expecting Qualigen Therapeutics to pay a dividend over the next 12 months.

Have Qualigen Therapeutics's shares ever split?

Qualigen Therapeutics's shares were split on a 1:25 basis on 25 May 2020. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Qualigen Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Qualigen Therapeutics shares which in turn could have impacted Qualigen Therapeutics's share price.

Qualigen Therapeutics overview

Qualigen, Inc. , a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site